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Gene discoveryMining of the genome for lipid genes has since the early 1970s helped to shape our understanding of how triglyc-
erides are packaged (in chylomicrons), repackaged (in very low density lipoproteins; VLDL), and hydrolyzed, and
also how remnant and low-density lipoproteins (LDL) are cleared from the circulation. Gene discoveries have
also provided insights into high-density lipoprotein (HDL) biogenesis and remodeling. Interestingly, at least
half of these key molecular genetic studies were initiated with the beneﬁt of prior knowledge of relevant
proteins. In addition, multiple important ﬁndings originated from studies in mouse, and from other types of
non-genetic approaches. Although it appears by now that the main lipid pathways have been uncovered, and
that only modulators or adaptor proteins such as those encoded by LDLRAP1, APOA5, ANGPLT3/4, and PCSK9 are
currently being discovered, genome wide association studies (GWAS) in particular have implicated many new
loci based on statistical analyses; these may prove to have equally large impacts on lipoprotein traits as gene
products that are already known. On the other hand, since 2004 – and particularly since 2010 when massively
parallel sequencing has become de rigeur – no major new insights into genes governing lipid metabolism have
been reported. This is probably because the etiologies of true Mendelian lipid disorders with overt clinical
complications have been largely resolved. In the meantime, it has become clear that proving the importance of
new candidate genes is challenging. This could be due to very low frequencies of large impact variants in the
population. It must further be emphasized that functional genetic studies, while necessary, are often difﬁcult to
accomplish, making it hazardous to upgrade a variant that is simply associated to being deﬁnitively causative.
Also, it is clear that applying a monogenic approach to dissect complex lipid traits that are mostly of polygenic
origin is the wrong way to proceed. The hope is that large-scale data acquisition combined with sophisticated
computerized analyses will help to prioritize and select the most promising candidate genes for future research.
We suggest that at this point in time, investment in sequence technology driven candidate gene discovery could
be recalibrated by refocusing efforts on direct functional analysis of the genes that have already been discovered.
This article is part of a Special Issue entitled: From Genome to Function.
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Plasma levels of low-density lipoprotein (LDL) cholesterol, high-
density lipoprotein (HDL) cholesterol and triglycerides (packaged in
very low-density lipoprotein [VLDL] and chylomicrons) are highly
complex traits, whose variation is estimated to be determined by an
equal impact of genetic and environmental factors [59]. Because of the
strong correlations between these traits and the risk of cardiovascular
disease [42], which is the main cause of death worldwide, lipoproteins
enjoy considerable scientiﬁc, public health and commercial interest.
This review focuses on the genetic origins of the major plasma lipid
traits that have been identiﬁed in both humans and mice. The primary
objectives were to acquire insight into how genes that impact plasma
lipid traits have been identiﬁed thus far, to critically assess themethodol-
ogies (and their challenges) that are currently used to identify possible
new candidate genes, and to draw a picture of what the future may
bring. We have also addressed the translational aspects of the work
conducted thus far, raising questions such as: To what extent have
1994 J.A. Kuivenhoven, R.A. Hegele / Biochimica et Biophysica Acta 1842 (2014) 1993–2009ﬁndings in humans been validated inmice or the other way around? And
to what extent have associations between genetic variation and plasma
lipid levels been validated through mechanistic studies?
In an attempt to constrain and disentangle the vast amount of
literature on this topic, monogenic causes for the main (primary)
dyslipidemias were distinguished from single gene causes for other
clinical or metabolic states for which dyslipidemia is a clinically
relevant manifestation or secondary feature. Thus, gene variation with
strong human evidence of an impact on plasma lipid levels was used as
the starting point in our review. With this criterion, studies of plasma
lipid metabolism in mice were also considered. Here, we worked to
distinguish between those investigations that were performed primarily
to translate initial ﬁndings in humans, natural and inbred strains of
mice, and those studies that were carried out to better understand
murine physiology, but coincidentally affected plasma lipids, and/or
studies to directly deﬁne the basis of murine dyslipidemia.
2. Studies of the genetics of primary or secondary dyslipidemias of
patients
Human genetics has long provided key insights into genes, gene
products and ultimately physiological pathways that govern plasma
lipoprotein metabolism.While perhaps over-used, the concept remains
valid that a naturally occurring genetic variant, which causes a clinically
signiﬁcant phenotype indicates that the mutated gene product (and
thus the wild type gene product) must be relevant to human physiolo-
gy. But while this concept is generally sound, it does not automatically
follow that gene products identiﬁed through human monogenic
syndromes are appropriate targets for the development of treatments.
Nonetheless, there are several approved or investigational agents whose
origin can be traced to the identiﬁcation of a human genetic defect, e.g.
PSCK9 inhibitors, CETP inhibitors, MTTP inhibitors (lomitapide), apo B
antisense RNA (mipomersen), and LPL gene therapy (glybera), among
others.
Human dyslipidemias can result either from the strong effect of a rare
mutation in a single gene, or from the cumulative small effects of
common variants or polymorphisms from several different genes. The
former group of dyslipidemias is termed “monogenic”, in that a single
genemutation fully explains the phenotype; an attempt at a comprehen-
sive list of these is shown in Table 1. This group of disorders contrasts
with the much more common “polygenic” dyslipidemias, which are
now understood to be the consequence of a state of genetic susceptibility
that is due to unfortunate simultaneous inheritance of multiple suscepti-
bility alleles (marked by single nucleotide polymorphisms or SNPs).
Often, genetic susceptibility is insufﬁcient to force the expression of the
phenotype, and additional factors – such as poor diet, non-ideal body
weight, inactivity or a range of medical conditions or medications – is
required for a genetically susceptible individual to express the phenotype.
Table 1 lists the single gene causes for the main dyslipidemia states
encountered in the clinic, subdivided according to the primary lipid
disturbance. These disorders display classical Mendelian inheritance
meaning that the disease is caused by mutations in single genes that
are inherited following a simple pattern. The identiﬁcation of the
causative mutation in the DNA of an affected individual is typically
required to implicate a gene as causative for a disorder. But there are
several ways to ﬁnd the causative mutation. In this regard, it is of
interest that about half of the genes with causative mutations were
discovered as the result of a priori knowledge of the protein product;
this prior understanding was used to guide the discovery or cloning of
the relevant gene within which the causative mutation was subse-
quently found. The availability of patients with extreme dyslipidemia
has been essential in these investigations. Another ~20% of causative
gene mutations for monogenic dyslipidemias were found using genetic
mapping approaches such as linkage analysis (positional cloning), in
which prior biochemical or other knowledge was ignored (or unavail-
able). Here, the position of the mutation within the genome led tostatistically implicating the gene locus as causative, with subsequent
studies focusing on understanding the gene product's function and
role. It is further interesting that despite considerable effort, after
more than 3 years high throughput massively parallel DNA sequencing
approaches have generally not identiﬁed new causes ofmonogenic dys-
lipidemia but merely conﬁrmed the role of already established genes
(further discussed below).
Table 2 lists the single gene causes for other clinical or metabolic
states that are not primarily characterized by dyslipidemia, but for
which dyslipidemia is a clinically relevant manifestation or secondary
feature. Disorders characterized include inherited lipodystrophies,
which feature elevated triglycerides and depressed HDL cholesterol as
key metabolic traits. Furthermore, inherited conditions such as: 1)
familial obesity syndromes; 2) familial insulin resistance syndromes;
3) some forms of familial diabetes, such as certain subtypes of maturity
onset diabetes of the young (MODY); 4) disorders that affect biosynthe-
sis of cholesterol or bile acids; and 5) multisystem disorders that may
seem unlinked to dyslipidemia, but which feature (albeit variably) a
range of severity of deviation of these traits. Another category of
diseases that seem to ﬁt here are congenital disorders of glycosylation.
While homozygotes or compound heterozygotes for loss of function
mutations suffer from severe complications, heterozygotes for such
mutations were recently shown to present with signiﬁcant changes in
plasma lipid levels [68]. In this case, aberrant glycosylation of proteins
that play primary roles in lipid metabolism is associated with dyslipid-
emia. Overall, it appears that elevated triglycerides and depressed HDL
cholesterol are the most sensitive lipid parameters that are affected by
metabolic disturbances in more distal pathways. It is also possible that
genes listed in Table 2 might be playing a role in the etiology of more
complex dyslipidemia phenotypes.
3. Studies of the genetics of lipid metabolism in mice
In an attempt to synthesize and arrange the studies into the genetics
of plasma lipid metabolism in mice, three categories were identiﬁed.
3.1. Studying the molecular genetics of human dyslipidemias
Section 1 of Table 3 lists the genes as the topic of the mouse studies
that were primarily initiated to further evaluate the molecular etiology
of genetic ﬁndings from patients with primary dyslipidemia (Table 1)
and from GWAS of populations. In order to be complete but concise,
only key papers that describe knockoutmice aswell asmice overexpress-
ing the gene of interest were cited. To keep Table 3 and the list of refer-
ences manageable, not all studies could be referenced; for instance, we
have limited citations to one or at most two studies on knockout/silenc-
ing, as well as on overexpression.
In many cases, knockout studies revealed murine plasma lipid
phenotypes that faithfully reﬂected those identiﬁed in humans. There
are, however, several exceptions. For example, deleting Apoa1 in mice
does not lead to HDL deﬁciency [205], while the analogous defect in
humans causes HDL deﬁciency. In contrast, loss of APOA2 in humans
has a minimal effect on lipid levels [41] (and has therefore not been
listed in Table 1), while Apoa2 knockout mice show reduced HDL
cholesterol levels [202]. On the other hand, there are reports on the
correlation between apoA-II and HDL cholesterol levels [18] (for a review
see [32]), so the issue is not yet resolved. Furthermore, loss of key genes in
plasma triglyceride lipolysis does not cause early (neonatal) death in
humans, as evidenced by long term survival among patients with LPL
and APOC2 deﬁciencies, while inmice such losses can have a large impact
on viability [201].
In addition, Lipa knockout mice appear normolipidemic while
patients with Wolman disease or CESD due to LIPA mutations show
increased concentrations of total cholesterol, LDL cholesterol and
triglycerides, with decreased HDL cholesterol [17]. In some cases, the
natural lack of CETP in mice can explain the discrepancies between
Table 1
Gene discovery in monogenic dyslipidemias according to primary lipid disturbance.










Sitosterolemia, elevated plasma plant sterols, but can present initially
as hypercholesterolemia
APOB Apolipoprotein B A priori knowledge of protein 107730 [178] Familial defective apo B (autosomal dominant hypercholesterolemia type 2)
LDLRAP1
(ARH)
LDL receptor associated protein 1 Linkage mapping 605747 [58] Autosomal recessive hypercholesterolemia
LDLR LDL receptor A priori knowledge of protein 606945 [105] Tour de forcemultifaceted approach to discover the basis of familial
hypercholesterolemia and the process of receptor mediated endocytosis
LIPA Lysosomal acid lipase Whole exome sequencing plus a priori
knowledge of protein
613497 [180] Known causative gene for cholesterol ester storage disease and Wolman
syndrome seen in “simple” hypercholesterolemia
PCSK9 Proprotein subtilisin/kexin 9 Linkage mapping in hypercholesterolemia 607786 [2] Autosomal dominant hypercholesterolemia type 3
Depressed LDL cholesterol
ANGPTL3 Angiopoietin like 3 Mouse studies plus whole exome sequencing 604774 [130] Familial combined hypolipidemia, a complex phenotype that
includes reduced TG and HDL cholesterol
APOB Apolipoprotein B A priori knowledge of protein 107730 [211] Hypobetalipoproteinemia; autosomal dominant inheritance,
parents have reduced LDL cholesterol
PCSK9 Proprotein subtilisin/kexin 9 A priori knowledge from linkage analysis plus
sequencing population extremes of LDL cholesterol
607786 [39] No associated syndrome or other systemic involvement
MTTP Microsomal triglyceride transfer protein A priori knowledge of protein 157147 [170] Abetalipoproteinemia; autosomal recessive inheritance, parents have normal lipid proﬁle
SAR1B Saccharomyces cerevisiae homolog 1B
(also known as SARA2)
Linkage mapping 607690 [83] Anderson disease; homozygous mutations in Sar1 GTPase of COPII
vesicles; low cholesterol with normal TG
MYLIP
(IDOL)
Myosin regulatory light chain interacting protein;
inducible degrader of the LDL receptor
In vitro studies [214] 610082 [179] Identiﬁed heterozygous truncation mutations in hypocholesterolemic individuals
Elevated HDL cholesterol
CETP Cholesterol ester transfer protein A priori knowledge of protein 118470 [25] CETP deﬁciency, hyperalphalipoproteinemia
LIPC Hepatic lipase A priori knowledge of protein 151670 [65] Hepatic lipase deﬁciency; complex dyslipidemia, including elevated HDL cholesterol
Depressed HDL cholesterol
APOA1 Apolipoprotein A-I A priori knowledge of protein 107680 [195] Some deletions affecting ≥2 genes at the APOA1–C3–A4–A5 cluster
have more complex phenotypes
LCAT Lecithin:cholesterol transfer protein A priori knowledge of protein 606967 [56,60] Causative for LCAT deﬁciency and ﬁsh eye disease; both of
which are associated with very low HDL cholesterol
ABCA1 ATP cassette binding protein A1 Linkage mapping 600046 [20,22,166] Causative for Tangier disease and familial hypoalphalipoproteinemia
Elevated triglycerides
APOA5 Apolipoprotein A-V Bioinformatics 606368 [117] Chylomicronemia in adults
APOC2 Apolipoprotein C-II A priori knowledge of protein 608083 [40] Cofactor for lipoprotein lipase activity
APOE Apolipoprotein E A priori knowledge of protein 107741 [38] Dysbetalipoproteinemia; combined hypercholesterolemia and
hypertriglyceridemia
GPD1 Glycerol-3-phosphate dehydrogenase 1 Linkage mapping 138420 [13] Transient infantile hypertriglyceridemia
GPIHBP1 Glycosylphosphatidyl inositol (GPI)-anchored high-
density lipoprotein (HDL)-binding protein 1
Human homologue of mutation in
induced mutant mouse
612757 [15] Chylomicronemia in adults
LMF1 Lipase maturation factor 1 Human homologue of mouse cld gene 611761 [149] Chylomicronemia in adults
LPL Lipoprotein lipase A priori knowledge of protein 118470 [50] Classical lipoprotein lipase deﬁciency
SLC25A49 Solute carrier 25 member 40 Linkage studies plus whole exome sequencing 610821 [161] Rare variants in families and populations associated with moderately increased triglycerides
Depressed triglycerides
APOC3 Apolipoprotein C-III Genome-wide association analysis in a
religious isolate
107720 [151] Mutation carriers comparedwith non-carriers also had lower fasting and postprandial TG, higher
















Human genetic disorders with a secondary dyslipidemia component.
Gene ID Protein OMIM Reference Comments
1) Lipodystrophies: elevated triglycerides and depressed HDL cholesterol
AGPAT2 1-Acyl-sn-glycerol-3-phosphate acetyltransferase 603100;
608594
[4,197] Lipodystrophy, congenital generalized, type 1
AKT2 Phosphoinositide-dependent serine-threonine protein kinase Akt iso-
form 2
164731 [168] Lipodystrophy with type 2 diabetes
BSCL2 Seipin 606158;
269700
[115] Lipodystrophy, congenital generalized, type 2
CAV1 Caveolin 1 601047;
612526
[91] Lipodystrophy, congenital generalized, type 3
CIDEC Cell-death inducing DFFA like effector C 612120;
615238
[163] Lipodystrophy, familial partial, type 5
LMNA Lamin A/C 150330;
151660
[30] Lipodystrophy, familial partial, type 2
PLIN1 Perilipin 1 613877;
170290
[57] Lipodystrophy, familial partial, type 4
PPARG Peroxisome proliferator activated receptor gamma 601487;
604367
[64] Lipodystrophy, familial partial type 3
PTRF RNA polymerase 1 and transcript release factor 603198;
613327
[63] Lipodystrophy, congenital generalized, type 4
ZMPSTE24 Zinc metalloproteinase STE24 606480;
608612
[5] Mandibuloacral dysplasia with lipodystrophy
2) Inherited insulin resistance and obesity syndromes: elevated triglycerides and depressed HDL cholesterol





Group of related disorders, including Leprechaunism (Donahue syndrome), Rabson–Mendenhall syndrome and Type A insulin
resistance
LEP Leptin 164160 [123]
3) Maturity-onset diabetes of the young (MODY) syndromes




MODY type 3; some individuals have metabolic syndrome with elevated triglyceride levels
HNF4A Hepatic nuclear factor 4-alpha 600281;
600496
[181] MODY type 4; some individuals have low triglyceride levels
4) Monogenic disorders of bile acid metabolism and cholesterol biosynthesis
SLC10A2 Ileal sodium bile salt transporter 601295;
613291
[138] Primary bile acid malabsorption, with congenital diarrhea, steatorrhea, and reduced plasma cholesterol
DHCR7 Sterol delta-7 reductase 270400;
602858
[136] Children with Smith–Lemli–Opitz syndrome have reduced levels of total cholesterol
5) Monogenic multisystem disorders with incidental dyslipidemia
FBN1 Fibrillin 1 134797 [61] Unusual single family with Marfan syndrome, progeroid features and hypertriglyceridemia
G6PC Glucose-6-phosphatase 613742;
232200
[106] Type 1a glycogen storage disease (von Geirke); hypertriglyceridemia can be severe
GK Glycerol kinase 300474;
307030
[198] Glycerol kinase deﬁciency causes factitious hypertriglyceridemia
JAG1 Jagged 1 118450;
601920
[100] Children with Alagille syndrome show increased levels of total and LDL cholesterol and triglycerides
SMPD1 Sphingomyelin phosphodiesterase 1 607608; [102] Atypical single family with Niemann Pick disease type B and very low HDL cholesterol
TNFRSF6 Tumor necrosis factor receptor superfamily member 6 601859;
134637
















Mouse studies 1) into the molecular genetics of human dyslipidemia; 2) into genomic regions/genes that control plasma lipid levels in mice, and studies that 3) happened to reveal dyslipidemic phenotypes.
Gene ID Protein Discovery Model Reference Lipid phenotype
1) Studying the molecular genetics of human dyslipidemias
Abca1 (Tangier disease) ATP binding cassette transporter Human genetics Transgenic overexpression
Knockout
[85,139,176] Elevated HDL cholesterol
Near HDL deﬁciency
Abcg5/g8 (sitosterolemia) ATP-binding cassette transporters
(ABC) G5 and G8
Human genetics Transgenic overexpression




No effect on plasma lipids
Sitosterolemia, reduced plasma cholesterol
(increased on upon cholesterol feeding)






Normal HDL cholesterol (apoE rich HDL)

















Lower total, HDL and LDL cholesterol










Apoc2 Apolipoprotein C-II Human genetics Transgenic overexpression [152] Hypotriglyceridemia.






Hypotriglyceridemia; loss of post-prandial
hypertriglyceridemia
Apoc4 Apolipoprotein C-IV Interest in (apo)lipoprotein
genetics
Transgenic overexpression [8] Hypertriglyceridemia
Apoa1, c3, a4 Apolipoprotein A-I C-III and A-IV Human genetics Knockout [122] Hypoalphalipoproteinemia but also low total
cholesterol and triglycerides




Apoe, apoc1 Apoe3 Leiden Human genetics Overexpression of human
apoE variant and apoC1
[190] Hypertriglyceridemia, hypercholesterolemia
CETP Cholesteryl ester transfer protein Human genetics Transgenic expression
of human CETP







[184] Reduced HDL cholesterol
Increased HDL cholesterol
Gpd1 Glycerol-3-phosphate dehydrogenase 1 Human genetics Knockdown [23,24] No apparent effects on plasma lipids
Lcat (familial LCAT deﬁciency,
ﬁsh-eye disease)










Lysosomal acid lipase Human genetics Knockout [45] Normal cholesterol and triglyceride levels













Elevated LDL and IDL cholesterol
Ldlrap1 (autosomal recessive
hypercholesterolemia)
Low-density lipoprotein receptor adaptor protein 1 Human genetics Whole body knockout [84] Elevated LDL cholesterol
Lpa Lipoprotein (a) Human genetics Apo(a) and apo B-100 double trans-
genic overexpression
[29] Increased Lp(a)-like particles





Lowered triglyceride and elevated HDL cholesterol
Severe hypertriglyceridemia and low HDL
cholesterol
Mttp1 (abetalipoproteinemia) Microsomal triglyceride transfer protein Human genetics Knockout [154] Embryonic lethal (homozygotes); low apo B con-
taining lipoproteins (heterozygotes)
















Gene ID Protein Discovery Model Reference Lipid phenotype
Bscl2 Seipin Human genetics Knockout [43] Hypotriglyceridemia






Smpd1 (Niemann Pick disease) SMA, acid sphingomyelinase Human genetics Knockout [70] Elevated cholesterol especially due to an increase in
HDL cholesterol
Sort1 Sortilin 1 Identiﬁed through GWAS [184] Overexpression using AAV
Knockdown (siRNA)
[131] Reduced LDL cholesterol
Increased LDL cholesterol
Pcpe2 Procollagen C-proteinase enhancer-2 GWAS [66] in vitro conﬁrmation
[217]
Knockout [55] Increased HDL cholesterol
Ppp1r3b Protein phosphatase 1, regulatory (inhibitor) subunit 3B Identiﬁed through GWAS [184] Viral overexpression [184] Reduced HDL cholesterol




Ttc39b Tetratricopeptide repeat domain 39B Identiﬁed through GWAS [184] Viral silencing [184] Increased HDL cholesterol
Znf202 Zinc ﬁnger protein Znf202 human genetics [197] Adenoviral Znf202 transfer to
Ldlr−/−mice and wild type mice
[196] Hypoalphalipoproteinemia
2) Identiﬁcation of loci that control plasma lipid levels in mice








Ath1 Ath1 (linked to Alp-2) Recombinant inbred strains Genetic mapping of mouse locus [141,142] Decreased HDLc with fat feeding
Txnip (Hyplip1) Thioredoxin interacting protein HcB-19/Dem mutant mouse strain Genetic mapping of mouse locus [19] Hypertriglyceridemia and hypercholesterolemia
Lmf1 (combined lipase
deﬁciency; cld)
Lipase maturating factor 1 Cross breeding and phenotyping Knockout [144] Hypertriglyceridemia








Octn2 Organic cation transporter family member 2 Targeted deletion and yeast artiﬁcial
chromosome rescue
Induced 450 kb deletion on
chromosome 11
[218] Hypertriglyceridemia
Mutation on chromosome 4 Protein unknown Spontaneous obesity in inbred DCW
strain
Spontaneous dbPAS mouse model [11,95] Hypercholesterolemia
Ror-alpha RAR-related orphan receptor alpha Deletion in Ror-alpha gene Sg/sg mutant mouse [116] Hypoalphalipoproteinemia; lowered intestinal apoA-
I expression
3) Genetically engineered mice showing dyslipidemia
Acl ATP-citrate lyase Dedicated to study cellular glucose




Ar Androgen receptor Study impact of AR on energy bal-
ance
Adipose-speciﬁc deletion in mice [212] Hypotriglyceridemia; hypocholesterolemia
Beta(1)AR Beta 1 adrenergic receptor Dedicated to study impact on energy
homeostasis
Knockout [187] Hypercholesterolemia, and hypertriglyceridemia
















Protein Discovery Model Reference Lipid
phenotype







fasting but hypotriglyceridemia upon feeding





Improves hypertriglyceridemia on high fat diet
Aqp1 Aquaporin-1 Study its impact on dietary fat
processing
Knockout [113] Hypotriglyceridemia
Creb3l3 CREBH (endoplasmic reticulum-tethered transcription fac-
tor cAMP responsive element-binding protein)
Study its function in hepatic
lipogenesis
Knockout
Forced expression of activated form
[215] Hypertriglyceridemia
Reduced plasma TG
FoxO1 Forkhead box-containing protein of the O subfamily (FoxO)
1
Studying metabolic syndrome Expression of constitutively active
FoxO1
[92] Hypertriglyceridemia due to increased food intake
Hnf3 Hepatocyte nuclear factor 3 alpha Dedicated to study impact on
physiology
Knockout [171] Hypotriglyceridemia






increased serum bile acid concentration
Hmgcr 3-Hydroxy-3-methylglutaryl coenzyme A reductase Study the role of hepatic HMGCR Liver-speciﬁc deletion [132] Hypercholesterolemia
Il2ra Interleukin receptor antagonist Study effect on cholesterol
metabolism
Knockout [76] Hypercholesterolemia
Mgl Monoglyceride lipase To characterize the role of MGL
in vivo
Knockout [183] Hypotriglyceridemia
nNOS/iNOS/eNOS N, inducible and endothelial nitric oxide synthase Dedicated to study impact of entire
NOS system
Triple knockout [133] Hypertriglyceridemia
Pcyt1a CTP:phosphocholine cytidylyltransferase alpha Interest in effects of CDP pathway in
lipoprotein metabolism.
Knockout [77] Decreased HDL cholesterol
Pemt Phosphatidylethanolamine N-methyltransferase Interest in PC biosynthesis Knockout [135] Reduced triglycerides in males
Rlip76 Glutathione-conjugate transporter Studying impact of Rlip76 on
metabolic syndrome
Knockout [177] Hypotriglyceridemia; hypocholesterolemia
Scap (SREBP pathway) ER-to-Golgi transport protein Study downregulation of SREBP
pathway through Scap deletion
Scap deﬁciency and knockdown [124] Rescue of carbohydrate induced
hypertriglyceridemia
Scd1 Stearoyl-CoA desaturase-1 Study metabolic changes Knockout [54] Hypercholesterolemia; hypoalphalipoproteinemia
Slc10a2 Ileal sodium-dependent BA transporter Studying impact of hepatic acetate
pool on TG metabolism
Knockout [111] Hypotriglyceridemia
Sod1 Superoxide dismutase Study impact of oxidative stress Knockout [97] Lack of post-prandial lipemia on high fat diet
sPLA2 Phospholipase A2 group IIA Study origin of reduced plasma
cholesterol.
Transgenic overexpression of human
sPLA2
[48] Hypocholesterolemia
Tsc22d4 Transforming growth factor beta 1-stimulated clone (TSC)
22 D4
Generated to study energy
homeostasis
Liver-speciﬁc deletion in mice [82] Hypertriglyceridemia
Xbp1 X box binding protein 1 Studying transcriptional regulation
of MHC class II [110]








































































































































































































































































































































































































































































































































































































































































































































































































2000 J.A. Kuivenhoven, R.A. Hegele / Biochimica et Biophysica Acta 1842 (2014) 1993–2009humans and mice, in view of its role in exchanging neutral lipids
between lipoproteins in the circulation. This can be appreciated by the
effects of the introduction of human CETP in mice, which results in
reduced HDL cholesterol and increased LDL cholesterol [80].
Section 1 of Table 3 also includes studies in mice that were conduct-
ed following the identiﬁcation of candidate genes through GWAS:
Galnt2, Sort1, Pcpe2, Ppp1r3b, Trib1, and Ttc39b. While these studies
have been critical to undertake, the impact of the ﬁndings has so far
been minimal — for instance, none of these gene products can be
deﬁnitively superimposed on known classical lipoprotein metabolic
pathways. In each case, more work is required, and as deﬁnitive
evidence accumulates, our understanding of lipoprotein metabolism
networks and interactions will only deepen and increase. As far as we
understand, a rare loss of function of gene defect that has been demon-
strated anticipated effects on lipid levels has been described only for
GALNT2 to date [68].3.2. Identiﬁcation of loci that control plasma lipid levels in mice
Section 2 of Table 3 lists studies of natural or spontaneous dyslipid-
emic mouse models. While a natural model of Apoe deﬁciency
mimicked the main biochemical ﬁndings in humans, translation into
human relevance of the ﬁndings for putative loci in other strains, such
as Ath1, Octn2, Ror-alpha have – again to our knowledge – not been
reported. On the other hand, in the case of combined lipase deﬁciency,
mutations in LMF1 were also shown to cause hypertriglyceridemia in
humans [149].3.3. Genetically engineered mice showing dyslipidemia
Section 3 of Table 3 is our attempt to enumerate studies of genetical-
ly engineered mice that in many cases “happened to show” dyslipid-
emic phenotypes. The rationale for studying the respective genes in
the ﬁrst place is very diverse and included interrogations to address ini-
tial hypotheses relevant to energy homeostasis, metabolic syndrome,
lipogenesis, glucose metabolism and even more remote are such as im-
munology and inﬂammation. The studies illustrate the close interac-
tions between the numerous research disciplines with lipid and
lipoprotein metabolism. As such, most of the effects on lipoprotein phe-
notypes listed here could easily be categorized as secondary, analogous
to the human examples listed in Table 2. However, one may bear in
mind thatmutations in some genes listed here can have a very large im-
pact. For example, heterozygous human mutations in CREB3L3 have
been reported to be associated with severe hypertriglyceridemia
[103], although only as a component of a polygenic pattern, and not
due to simple Mendelian genetics in families. In mice, it was speciﬁcally,
shown to be due in part to defective expression of several co-activators of
lipoprotein lipase (LPL), including Apoc2, Apoa4 and Apoa5 together with
augmentation of the LPL inhibitorApoc3. TheCREB3L3 example shows the
ﬁne and sometimes arbitrary line between genetically determinedprima-
ry and secondary dyslipidemia.3.4. Nonconforming examples
In order to adhere to the spirit of the title of this review, ABCG1 has
not been included in our syntheses because both knockout as well as
transgenic overexpression did not reveal changes in plasma lipid levels
[89] although changes in non-essential free fatty acids have been
reported [26]. Also, variation in the human ABCG1 promoter reported
thus far does not affect plasma lipid in humans, although it did have
an impact on cardiovascular outcome [167]. In addition, we did not
list the effects of transient expression of apo A-I mutants in mice,
which led to a range of lipid phenotypes includinghypocholesterolemia,
hypoalphalipoproteinemia and hypertriglyceridemia [35,36].
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In this review, we limited ourselves to studies of dyslipidemia inmice
since this species has been the preferred animal of choice of most inves-
tigators in the lipoprotein ﬁeld. There are however naturally occurring
models of dyslipidemia that deserve mentioning, including LDLR
deﬁciency in WHHL rabbits (for a review please see [94]), ABCA1
deﬁciency in chicken [10], and LPL deﬁciency in mink [34] and cats
[148].
Also there are several interesting lines of dyslipidemic rabbits
including the TGH rabbit [174] with increased triglyceride and
cholesterol (reviewed in [44]). In addition, transgenic rabbit models
have been generated to study target genes (for a review please see
[146]). The advantage of this species is that rabbits like humans
naturally express CETP and are also prone to develop diet-induced
atherosclerosis.
Finally, there are several lines of dyslipidemic rats, such as the LEC rat
(a model forWilson disease), which displays increased triglycerides, free
cholesterol and cholesteryl ester due to a defect in Atp7b [107]. However,
humanWilsondisease patients are not typically dyslipidemic. In addition,
a number of rat strains display hypertriglyceridemia as the primary lipid
disturbance, including the Prague hereditary hypertriglyceridemic (HTG)
rat [86], the analbuminemic Nagase rat (NAR) [52], the Spontaneously
Diabetic Torii rat [175] and the JCR:LA corpulent rat [165].
To our knowledge, the genetic origins of dyslipidemic pheno-
types in the majority the above rabbit and rat models have not yet
been uncovered, indicating that they remain an interesting source of
new candidate genes. However, it is possible that the underlyingmolecu-
lar biology in at least someof these strains has a polygenic origin and their
lipid phenotype is a proxy of multiple metabolic derangements. In this
regard, special initiatives such as The Collaborative Cross may help by
providing an integrative analysis of complex systems [37] rather than a
strong emphasis on monogenic origins of disease in the lipid ﬁeld.
4. In vitro and other approaches that led to the discovery of genes
that affect plasma lipid levels
Table 4 lists some major lipid genes that have been identiﬁed using
various other methods. The outcome of four expression studies appears
to dominate this table, while two reports describe the elegant use of
bioinformatics [62,147] in gene discovery. Following the initial publica-
tions listed here, several reports have provided unequivocal evidence of
a strong impact of rare mutations in the human orthologs. For example,
in individuals or patients with severe dyslipidemia who were referred
to the clinic, a complete loss of APOA5 or GPIHBP1 has been shown to
underlie severe hypertriglyceridemia or chylomicronemia. In the cases
of LIPG and SCARB1, functionalmutations have also been shown to affect
HDL metabolism in humans [90,194], but so far no individuals with
complete deﬁciencies have been identiﬁed. It is possible that a complete
loss of these genes is not compatible with life. Following upon the
studies of Atgl in mice, mutations in the human PNPLA2 gene were
shown to cause neutral lipid storage disease with myopathy [53], a
rare disorder that affects body fat distribution, without affecting plasma
lipid levels. Clearly, these gene identiﬁcation studies have greatly
advanced our understanding of human lipid metabolism. Furthermore,
for ApoM, Lrp1, Hsl, and Pltp genes, rare large impact mutations have so
far not been shown to affect plasma lipid levels in humans.
Finally, screening efforts investigating the role of low-frequency
variants have used both custom exome microarrays [145] and exome
sequencing [99]. The former approach identiﬁed no novel loci with
effects on either LDL cholesterol or CHD risk, but a few that had effects
on plasmaHDL cholesterol or triglycerides, namelyANGPTL8, PAFAH1B2,
COL18A1 and PCSK7 [145]. In contrast, exome sequencing found a
higher burden of low-frequency variants in PNPLA5, encoding a
phospholipase-domain-containing protein that was associated with
LDL cholesterol, in addition to both known and previously unidentiﬁedvariants in PCSK9, LDLR and APOB [99]. However, such ﬁndings seem to
indicate that PCSK9 is the exception rather than the rule for low-
frequency coding variants that have robust effects on both lipids and
CHD.
5. Identifying “the higher hanging fruit”
After a period duringwhich seminal discoveries from human genetics
of lipoproteins seem to come in rapid succession, such as homozygosity
for loss of function mutations in ABCA1 causing Tangier disease in 1999
[20,22,166] and that gain of function mutations in PCSK9 caused autoso-
mal dominant hypercholesterolemia in 2004 [1], the pace of discovery
of genes of this magnitude has slowed down. With more than 10 years
having elapsed since the discovery of PCSK9, and the apparent paucity
of ﬁndings with comparable clinical impact and translatability, it appears
that identifying and importantly subsequently validating the impact of
new loci on (plasma) lipid metabolism is not straightforward. It appears
that most if not all of “the lower hanging fruit” has been picked. In
addition, the recent remarkable advances in sequencing technology
have not yet allowed the harvest of “the higher hanging fruit” either, as
will be discussed below. One may wonder whether there are any more
major genes out there. This section brieﬂy describes the different
approaches – and their challenges – that are currently being employed
to identify new genes.
5.1. Use of families with extreme dyslipidemia
From 1970 onwards, reverse genetics has clearly been the most
important strategy to advance knowledge of lipoprotein genetics,
since at least 12 of the major genes governing lipoprotein metabolism
were discovered due to a priori knowledge of the function of their
protein products (see Table 1). Naturally, studies of families with severe
deviations of normal lipid traits have been instrumental in these inves-
tigations. In this light, it is rather surprising that despite major efforts
worldwide only 6 genes have been discovered solely through linkage
mapping in families, namely ABCG5/G8, LDLRAP1, PCSK9, SAR1B, ABCA1,
and GPD1. In other words, knowledge of these 6 genes came ﬁrst
through statistical identiﬁcation of the co-segregating chromosomal
segments in affected individuals, followed by narrowing down the
speciﬁc gene through the discovery of the causative mutation in affect-
ed family members. Study of the respective proteins followed, and the
importance of each gene and gene product in lipoprotein metabolism
was subsequently validated functionally, for instance in mouse studies.
In the cases of LDLRAP1 in autosomal recessive hypercholesterolemia
and GPD1 in transient infantile hypertriglyceridemia, the causative
mutations were present on both alleles and the pattern of inheritance
is autosomal recessive. It is however, likely, that additional novel disor-
ders of lipoprotein metabolism if they exist will follow an autosomal
dominant mode of inheritance. This group of disorders can be much
more difﬁcult to solve, especially considering that plasma lipid levels
are highly complex traits even within families with a strong single
genetic determinant. Another complication is that rare high impactmu-
tations are by deﬁnition rare and chances of ﬁnding de novomutations
or recessive lipid traits in families are indeed small. For instance, it has
taken 25 years to validate the role of LMF1 in human lipid metabolism
[149] and to date fewer than 10 index patients with chylomicronemia
due to mutations in LMF1 have been described. Non-penetrance and
phenocopies pose other serious impediments to these studies especially
in the face of a large effect size of lifestyle and environmental factors on
plasma lipid levels (most notably on HDL cholesterol and triglyceride
levels). Autosomal dominant traits are notorious for a tendency towards
variable penetrance, i.e. phenotypic differences in carriers of the same
mutation. Variable penetrance can confound mathematical modeling
of the co-segregation of a genetic variant and the trait on interest.
(Gene × gene) and (gene × environment) interactions add yet another
layer of complexity. With all these factors in mind, ﬁnding additional
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park. The polygenic nature of even extreme plasma lipid levels as has
recently been described for triglycerides [81], LDL cholesterol [182]
and HDL cholesterol [127], further emphasizes that gene ﬁnding efforts
in families will be challenging even in the best case scenario.
5.2. Use of exome or genome sequencing
The recent technological advances that have allowed for massively
parallel, high throughput DNA and RNA sequencing are yielding
successes almost daily in terms of discovering novel genes and novel
mutations underlying single gene syndromic disorders across a wide
range of disease entities and disciplines [21]. Most of these have been
autosomal recessive disorders, with somewhat less success in solving
autosomal dominant disorders to date. However, the impact of whole
exome sequencing (WES) or whole genome sequencing (WGS) upon
understanding lipoprotein metabolism has still to fulﬁll its promise.
For instance, an early WGS study performed in an infant with severe
hypercholesterolemia revealed that the patient was a compound
heterozygote for two nonsense mutations in the ABCG5 gene [157],
which was already known to be the cause of sitosterolemia. Similarly,
a heterozygous in-frame deletion in the APOE gene was found by WES
in two independent families with an apparently new form of autosomal
dominant familial hypercholesterolemia [12,118]. Also, WES identiﬁed
a homozygous splicing mutation in LIPA, the gene otherwise known to
cause cholesterol ester storage disease, in a patient with a recessive
form of hypercholesterolemia [180] while mutations in APOB were
again identiﬁed as a cause of hypercholesterolemia through WES [128].
Even the highest impact ﬁnding to date from a WES study – namely
identiﬁcation of ANGPTL3 as the causative gene for familial combined
hypolipidemia [130] – had homed in on a gene that was already known
to be involved in lipoprotein metabolism from earlier studies in mice
[173]. Thus, to date the application of massively parallel sequencing
technologies in familial dyslipidemia has thus far not really accelerated
our understanding of the genetics of lipoprotein metabolism.
5.3. Genome-wide association studies
The most recent update to the GWAS-generated list of loci associated
with plasma lipid traits was reported by Willer et al. [204], which added
62 loci to the original 95 loci reported in Nature in 2010 [184] now giving
a grand total of 157 loci. This Herculean feat was accomplished through
the use of enormous datasets of participants mainly from epidemiologic
studies of normolipidemic populations. The total number of study
subjects meta-analyzed reached almost 190,000 individuals of various
ethnicities. Included among the new 62 loci are 32 genes that have
some previous connection within lipoprotein metabolism, and 30 loci
for which there was no a priori role known.
Sixty ﬁve of the 157 GWAS loci so far discovered show signiﬁcant
associations with two or more of the four main lipid traits; four of these
show associations with all four of total, LDL and HDL cholesterol, and
triglycerides, namely CETP, TRIB1, FADS1-2-3 and APOA1. On the other
hand, 92 loci have exclusive associations with only a single lipid trait;
speciﬁcally 46, 18, 16 and 9 loci are associated with HDL cholesterol,
triglycerides, total cholesterol and LDL cholesterol, respectively. These
exclusive associations might be due to the small effect sizes and thus
borderline signiﬁcance for even a single trait for these new loci — the
second or third potential associated lipid trait for such loci may have
fallen below the adjusted genome-wide P-value. Most of the previously
unknown loci are found among these exclusive associations, and their
biology will be very interesting to sort out in the coming years.
It is deﬁnitely exciting that so many “new suspects” are represented
on the same list as many of the old “usual suspects” —with similar effect
sizes and at comparable levels of statistical signiﬁcance. But the initial
suggestion that GWAS-generated lists would point theway to new biolo-
gy andmechanismsmay have been premature; it has not yet yielded theanticipated bonanza of new understandings. After some consideration,
however, this is not unexpected in view of the time that passed since
the ﬁrst well-powered meta-analyses in 2008. The investments usually
needed to understand the molecular mechanisms of the phenomena
observedmay takemany years: e.g.despite the fact that ABCA1deﬁciency
concerned a severeMendelian disorder of HDLmetabolismwith a strong
biochemical and clinical presentation that had been studied by all major
HDL groupsworldwide, it took 15 years to establish ABCA1 as a phospho-
lipid transporter [153]. Furthermore, there is still no consensus on its
relationship with HDL cholesterol and risk of cardiovascular disease.
Another example is the relatively slow progress on how the SORT1
locus, identiﬁed by GWAS in 2008, affects LDL cholesterol levels [131].
Here the story is complicated and is far from being resolved [46,93,108]
despite the fact investigators were able to immediately beneﬁt from the
presence of Sort1 knockout mice. For a few other GWAS loci, mouse
studies have been conducted as described above but the translational
efforts are overall rather small.
Despite the strong statistics and large numbers of loci, the effect
sizes of the new loci are very modest: the new GWAS loci together
explain ~2% of the variation in the plasma lipid traits, which increases
the total explained by all GWAS loci to b15% [204]. The questions that
remain include: 1) where is the missing heritability when considering
that twin studies have indicated that plasma lipid levels are inherited
by at least 50%? [59]; and 2) even if the complete biology of all 157
GWAS-associated lipid loci is solved, how much of an increment of the
architecture of lipoprotein metabolism can this yield? Ongoing efforts
to examine phenomena such as the effects of independent variants at
known GWAS loci, the concept of pseudo-heritability and the pseudo-
inﬁnitesimal model may also help increase the overall contribution of
genetics to lipid traits.
In an attempt to pick the higher hanging fruit, the investigations so far
strongly focus on the new candidate genes with the highest statistical
association with the lipid trait(s) of interest. It may be noted, however,
that it is very difﬁcult if not impossible to estimate the possible impor-
tance of the products of genes in lipid metabolism with the help of
common genetic variation at the locus of interest as the natural frequency
of the genetic variation has e.g. a large effect on the outcome of such stud-
ies. To illustrate this, a loss of two functional LCAT alleles causes near HDL
deﬁciency but the DNA of 100,000 individuals was needed simply to
statistically link LCAT to HDL cholesterol levels [184].5.4. New bioinformatic approaches to identify and/or prioritize candidate
genes
The above sections summarize the challenges faced by the traditional
as well as the current state-of-the-art primarily technology-driven
approaches. So far, only two lipid genes have been discovered through
bioinformatics [62,147], but with contemporary means to generate
massive amounts of sequencing data from both DNA and RNA combined
with an apparent unlimited computational power, there remains hope
that genetic analyses will become more comprehensive and sophisticat-
ed. In other words, progress beyond genome wide association with
plasma lipid levels, for example, is needed to help zoom in on the full
range of causal molecular mechanisms.
We here brieﬂy describe recent developments based on the bioinfor-
matic use of other “omics” data. While becoming aware of the staggering
complexity of how the genome for example relates to HDL cholesterol
levels, as recently discussed by Morrison et al. [126], the use of mRNA
as proxy of the genome can help us in ﬁnding new pathways or new
adaptors/modulators of the established lipid pathways. The advantage
here is that mRNA array data are often in the public domain and the
technique has long been validated while the analysis of RNA sequencing
data is advancing at a high speed. It has now become possible to identify
the downstream effects of disease-associated SNPs through the expres-
sion of quantitative trait locus (eQTL)meta-analysis as recently described
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Another approach is to study the associations between whole
genome variations with concentrations of plasma enzymes to help ﬁnd
the genes that are causally related to liver disease for instance [31].
With access to genome wide variation data, one can alternatively also
focus on metabolite concentration ratios as a proxy of the enzymatic
reaction rates to reduce the work load [72].
Another promising strategy to identify novel key regulators of lipid
metabolism is to study proteins that have previously been shown to
interact with gene products that have established roles in lipid metabo-
lism. This may be especially promising in view of the importance of
reverse genetics in the early days of lipoprotein research. In other
words, the use of proteomic network analyses to create phenomes or
interactomes can help to shed new light on the origin of human disease,
a tactic that has already been proven to work [98]. One can imagine that
mutations in genes encoding proteins associated with, for example
ABCA1 function [67,188] can cause reductions of HDL cholesterol levels
in the circulation. Studieswith such a focusmay bemore successful than
agnostic screening of the genome or exome for mutations that cause
low HDL cholesterol for the simple reason that the number of potentially
functional mutations in the exome let alone the genome is extremely
large and mostly incidental; the role of any particular exomic variant
would be difﬁcult to distinguish from control individuals with normal
HDL cholesterol.
6. Perspectives and conclusions
The initial high impact publications on the identiﬁcation of major
lipid genes (see Tables 1, 3 and 4) have generally prompted extensive
follow-up investigations that have largely validated the important
roles of the respective gene products in lipid metabolism. In several
cases, such investigations have been greatly aided through the identiﬁ-
cation of frequent high impact mutations in patient populations, which
then vindicated their clinical relevance. For instance, mutations in the
LDLR could explain life-threatening hypercholesterolemia in a consider-
able number of patients in the general population. In contrast, LDLRAP1
has received very little attention due to the fact that mutations appear
to be very rare, despite the fact that its impact on LDL biology is very
signiﬁcant. More recently the very low frequency of functional mutations
in PCSK9 [1] made it initially difﬁcult to verify its importance in lipid
metabolism, which was further complicated by the identiﬁcation of
both gain as well as loss of function mutations. Instead studies into the
more common PCSK9 variants in larger population samples led to a
breakthrough that has had lasting concrete impact [39]. Here, the use of
large-scale rapid genotyping using tagging SNPsmoved the ﬁeld forward.
The same methodology was used to validate the importance of ANGPTL3
and ANGPTL4 in human HDL and triglyceride metabolism [159,160].
While such studies have advanced our understanding in such cases, not
all ﬁndings in humans have been replicated in mice or vice versa as can
be appreciated from Tables 1, 3 and 4. In some instances this may have
been due to species differences. Other reasons include the absence of
overt effects of gene variants on lipid metabolism, publication of initial
results in lower impact journals, the absence of larger scale candidate
gene studies in appropriate target populations, or simply the near
absence of large impact mutations, which in turn is directly related to
the size of the protein coding regions of the genes of interest. However,
the reality appears to be that the example of PCSK9 as a genetic-based
ﬁnding that could be rapidly translated clinically may be the exception
rather than the rule for genes involved in lipoprotein metabolism.
While the number of candidate genes available for further functional
studies was perhaps manageable prior to the publication of the ﬁrst
large-scale GWAS in 2008, this is no longer the case today, as discussed
above. This research community has just embarked on the monstrous
aftermath to understandwhether and viawhichmechanisms candidate
genes can affect lipid metabolism. There is now a pressing need for thedevelopment of high-throughput functional assays to help prioritize
and impose a sense of order and direction on this multitude of ﬁndings
[164]. The cornucopia of GWAS data is immense, but also immensely
hypothesis generating. At this point, perhaps it is worthwhile to stop,
take a deep breath and consider the impact of the trove of data already
in hand whether from the 95 original loci or the more complete list of
157 loci.
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